HURA

TuHURA Biosciences (HURA)

About TuHURA Biosciences (HURA)

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. Its lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded by Michael Lawman, Patricia Lawman and James A. Bianco on May 4, 2023 and is headquartered in Tampa, FL.

Details

Daily high

$2.72

Daily low

$2.52

Price at open

$2.58

52 Week High

$3.90

52 Week Low

$0.41

Market cap

163.7M

Dividend yield

0.00%

Volume

782,416

Avg. volume

508,513

P/E ratio

-4.26

TuHURA Biosciences News